inmunebio.jpg
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
July 23, 2024 08:45 ET | INmune Bio, Inc.
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics BOCA RATON, Fla., July 23, 2024 ...
RNAZ White background cropped.jpg
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 22, 2024 16:07 ET | TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
scilogo.jpg
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024 08:20 ET | SciSparc Ltd
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
ACF logo RGB - Used for Digital and MS Office (1).png
The Alberta Cancer Foundation’s Enbridge Tour Alberta for Cancer Passes $100 Million Milestone in its 16th Year
July 20, 2024 09:45 ET | Alberta Cancer Foundation
The 16th annual Enbridge Tour Alberta for Cancer in support of the Alberta Cancer Foundation marks $100M in total funds raised.
CytoMed logo.png
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
July 17, 2024 07:00 ET | CYTOMED THERAPEUTICS LIMITED
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Tevogen Logo Notified.png
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
July 11, 2024 12:21 ET | Tevogen Bio Inc
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
RM Primary Logo - Humble.png
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 11, 2024 12:00 ET | Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
logo 600X600.png
U.S. Colorectal Cancer Screening Market is Expected to Reach US$ 10,618.9 Million by 2031, CoherentMI
July 11, 2024 04:00 ET | CMI
Burlingame, July 11, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, U.S. Colorectal Cancer Screening Market is estimated to value at US$ 5,952.2 Million in the year 2024, and is...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
July 10, 2024 08:05 ET | Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet
July 10, 2024 08:00 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet